Format

Send to

Choose Destination
Dermatol Ther. 2019 Dec 31:e13215. doi: 10.1111/dth.13215. [Epub ahead of print]

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature.

Author information

1
Department of Dermatology, CNMC, Kolkata, India.
2
Department of Dermatology, CMSDH, Kolkata, India.
3
Worldwide laser institute, Dallas, Texas.
4
Military Medical Academy of Belgrade, Belgrade, Serbia.
5
Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey.
6
Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
7
Vitiligo Research Foundation, New York, New York.
8
Department of Dermatology, University of Studies Guglielmo Marconi, Rome, Italy.
9
Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran.
10
Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
11
Department of Dermatology, University of Rome G. Marconi, Rome, Italy.
12
Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
13
Department of Dermatology, University Hospital Basel, Basel, Switzerland.

Abstract

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as "vitiligo," "treatment," "recent," and "immunomodulators" to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.

KEYWORDS:

immunomodulators; new treatment; vitiligo

PMID:
31891450
DOI:
10.1111/dth.13215

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center